壮观霉素类似物U-63366、新型大环内酯类抗生素罗红霉素（RU 28965）以及五种喹诺酮衍生物对杜克雷嗜血杆菌的体外活性。
In vitro activities of U-63366, a spectinomycin analog; roxithromycin (RU 28965), a new macrolide antibiotic; and five quinolone derivatives against Haemophilus ducreyi.
作者信息
Sanson-Le Pors M J, Casin I M, Thebault M C, Arlet G, Perol Y
出版信息
Antimicrob Agents Chemother. 1986 Sep;30(3):512-3. doi: 10.1128/AAC.30.3.512.
Abstract
The in vitro activities of the new spectinomycin analog U-63366, the new macrolide roxithromycin (RU 28965), and five new quinolone derivatives (pefloxacin, rosoxacin, norfloxacin, ofloxacin, and ciprofloxacin) were studied against 23 multiresistant strains of Haemophilus ducreyi (beta-lactamase producers) isolated in Paris and were compared with the activities of tetracycline, minocycline, chloramphenicol, streptomycin, kanamycin, gentamicin, spectinomycin, erythromycin, and nalidixic acid. All strains were uniformly susceptible to the seven new antibiotics tested. Ciprofloxacin had the greatest inhibitory effect in vitro (the MIC for 90% of the strains tested [MIC90] was 0.016 microgram/ml), and U-63366 was the most active aminoglycoside-aminocyclitol antibiotic (MIC90, 0.25 microgram/ml).
摘要
研究了新型壮观霉素类似物U - 63366、新型大环内酯类药物罗红霉素（RU 28965）以及五种新型喹诺酮衍生物（培氟沙星、咯索沙星、诺氟沙星、氧氟沙星和环丙沙星）对在巴黎分离出的23株多重耐药性杜克雷嗜血杆菌（产生β - 内酰胺酶）的体外活性，并与四环素、米诺环素、氯霉素、链霉素、卡那霉素、庆大霉素、壮观霉素、红霉素和萘啶酸的活性进行了比较。所有菌株对所测试的七种新型抗生素均表现出一致的敏感性。环丙沙星在体外具有最大的抑制作用（所测试菌株中90%的最低抑菌浓度[MIC90]为0.016微克/毫升），而U - 63366是活性最高的氨基糖苷 - 氨基环醇类抗生素（MIC90为0.25微克/毫升）。
相似文献
1
In vitro activities of U-63366, a spectinomycin analog; roxithromycin (RU 28965), a new macrolide antibiotic; and five quinolone derivatives against Haemophilus ducreyi.
Antimicrob Agents Chemother. 1986 Sep;30(3):512-3. doi: 10.1128/AAC.30.3.512.
2
In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae.
Antimicrob Agents Chemother. 1984 Oct;26(4):608-9. doi: 10.1128/AAC.26.4.608.
3
Comparison of antimicrobial susceptibility patterns of fifty-seven strains of Haemophilus ducreyi isolated in Amsterdam from 1978 to 1985.
J Antimicrob Chemother. 1987 Feb;19(2):187-91. doi: 10.1093/jac/19.2.187.
4
The comparative in-vitro activity of twelve 4-quinolone antimicrobials against Haemophilus ducreyi.
J Antimicrob Chemother. 1985 Aug;16(2):165-8. doi: 10.1093/jac/16.2.165.
5
In-vitro susceptibility of thirty strains of Haemophilus ducreyi to several antibiotics including six cephalosporins.
J Antimicrob Chemother. 1983 Mar;11(3):271-80. doi: 10.1093/jac/11.3.271.
6
Correlation between in vitro antimicrobial susceptibilities and beta-lactamase plasmid contents of isolates of Haemophilus ducreyi from the United States.
Antimicrob Agents Chemother. 1992 Aug;36(8):1639-43. doi: 10.1128/AAC.36.8.1639.
7
Susceptibility of Haemophilus ducreyi to spectinomycin in vitro.
Genitourin Med. 1986 Aug;62(4):251-2. doi: 10.1136/sti.62.4.251.
8
Antimicrobial susceptibility and characterization of outer membrane proteins of Haemophilus ducreyi isolated in Thailand.
J Clin Microbiol. 1985 Mar;21(3):442-4. doi: 10.1128/jcm.21.3.442-444.1985.
9
In vitro activity of the new macrolide antibiotic roxithromycin (RU 28965) against clinical isolates of Haemophilus influenzae.
Antimicrob Agents Chemother. 1986 May;29(5):921-2. doi: 10.1128/AAC.29.5.921.
10
A comparison of the in vitro activity of rosamicin, erythromycin, clindamycin, metroidazole and ornidazole against Haemophilus ducreyi, including beta-lactamase producing strains.
J Antimicrob Chemother. 1979 Nov;5(6):731-4. doi: 10.1093/jac/5.6.731.
引用本文的文献
1
Mild and convenient -formylation protocol in water-containing solvents.
Tetrahedron Lett. 2013 Apr 17;54(16):2077-2081. doi: 10.1016/j.tetlet.2013.02.013.
2
Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Drugs. 1988 Apr;35(4):373-447. doi: 10.2165/00003495-198835040-00003.
3
Biotypes, serotypes, and susceptibility to antibiotics of 60 Haemophilus influenzae strains from genitourinary tracts.
Genitourin Med. 1988 Jun;64(3):185-8. doi: 10.1136/sti.64.3.185.
4
Activity of trospectomycin against Bacteroides fragilis and other Bacteroides species.
Antimicrob Agents Chemother. 1988 Apr;32(4):584-6. doi: 10.1128/AAC.32.4.584.
5
Quinolone antibacterial agents for the treatment of genitourinary tract infections.
Eur J Clin Microbiol Infect Dis. 1989 Dec;8(12):1111-6. doi: 10.1007/BF01975178.
6
New directions for macrolide antibiotics: structural modifications and in vitro activity.
Antimicrob Agents Chemother. 1989 Sep;33(9):1413-8. doi: 10.1128/AAC.33.9.1413.
7
Fluoroquinolone antimicrobial agents.
Clin Microbiol Rev. 1989 Oct;2(4):378-424. doi: 10.1128/CMR.2.4.378.
8
Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Drugs. 1989 May;37(5):628-68. doi: 10.2165/00003495-198937050-00003.
9
Roxithromycin. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.
Drugs. 1989 Jan;37(1):8-41. doi: 10.2165/00003495-198937010-00002.
10
Chancroid and Haemophilus ducreyi.
Clin Microbiol Rev. 1989 Apr;2(2):137-57. doi: 10.1128/CMR.2.2.137.
本文引用的文献
1
Antimicrobial susceptibility of 103 strains of Haemophilus ducreyi isolated in Johannesburg.
Antimicrob Agents Chemother. 1982 Oct;22(4):686-8. doi: 10.1128/AAC.22.4.686.
2
Detection of chloramphenicol acetyltransferase (CAT) activity in a strain of Haemophilus ducreyi.
Ann Microbiol (Paris). 1982 Sep-Oct;133(2):311-5.
3
Pharmacokinetics and tissue penetration of ciprofloxacin.
Antimicrob Agents Chemother. 1983 Nov;24(5):784-6. doi: 10.1128/AAC.24.5.784.
4
In-vitro susceptibility of thirty strains of Haemophilus ducreyi to several antibiotics including six cephalosporins.
J Antimicrob Chemother. 1983 Mar;11(3):271-80. doi: 10.1093/jac/11.3.271.
5
The plasmids of Haemophilus ducreyi.
J Antimicrob Chemother. 1984 Dec;14(6):561-4.
6
Antimicrobial therapy of chancroid: effectiveness of erythromycin.
J Infect Dis. 1983 Oct;148(4):726-31. doi: 10.1093/infdis/148.4.726.
7
Plasmid-mediated tetracycline resistance in Haemophilus ducreyi.
Antimicrob Agents Chemother. 1984 Feb;25(2):187-90. doi: 10.1128/AAC.25.2.187.
8
Drug of choice for chancroid.
Lancet. 1983 Jan 15;1(8316):125. doi: 10.1016/s0140-6736(83)91766-x.
9
Streptomycin-resistant Haemophilus ducreyi.
Lancet. 1982 Nov 6;2(8306):1043. doi: 10.1016/s0140-6736(82)90072-1.
10
Treatment of chancroid by clavulanic acid with amoxycillin in patients with beta-lactamase-positive Haemophilus ducreyi infection.
Lancet. 1982 Sep 4;2(8297):509-11. doi: 10.1016/s0140-6736(82)90597-9.
Zotero 插件